Skip to main content
Premium Trial:

Request an Annual Quote

EpiVax, BioAtla Collaborate on Antibody Screening Technology

NEW YORK (GenomeWeb News) – EpiVax's immunogenicity screening technology will be incorporated into BioAtla's antibody Express Humanization platform under a collaboration announced today.

Providence, RI-based EpiVax has developed in silico tools for the immunogenicity screening of protein therapeutics, immunogenicity mitigation, and T cell-driven vaccine design, while San Diego-based BioAtla's Express Humanization platform "entails synthesizing a combinatorial library of non-human target monoclonal antibodies fused in frame to a validated collection of human frameworks, and screening for binding, function, and expression."

Combining the two companies' technologies, they said, provides a third level clone selection criterion for developing human antibody therapeutics, immunogenicity, thereby expanding the functional selectivity of BioAtla's expression-based humanization process.

Financial and other terms of the deal were not disclosed.